Once-a-week Risedronate (Actonel)
A once-weekly 35-mg oral formulation of the bisphosphonate risedronate (Actonel) has been approved by the FDA for prevention and treatment of postmenopausal osteoporosis. A once-weekly formulation of alendronate (Fosamax) was approved last year (Medical Letter 2001; 43:26). Bisphosphonates bind to the mineral surface of bone and decrease osteoclast activity, inhibiting the resorption phase of the bone turnover cycle. These drugs are not metabolized and remain bound to bone for several weeks....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Once-a-week Risedronate (Actonel)
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1141
Article Code: 1141a
Date: October 14, 2002
Volume: 44
Pages: 87-88
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1141
Article Code: 1141a
Date: October 14, 2002
Volume: 44
Pages: 87-88
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)